4
The everyday ambitions of Home Peptides
Four compounds arrive with extravagant reputations. I’m interested in their smaller ambitions: a farther walk, comfortable movement, a change in skin, the return of desire.
Walking distance
Of all the outcomes in a 2023 NMN trial in middle-aged adults, walking distance is my favourite outcome. Over 60 days, the people receiving NMN had higher blood NAD+ than the placebo group; they also walked farther and reported better health and wellbeing. The blood measurements rose at 30 and 60 days. A walk gives the chemistry somewhere to go.
NMN supplies material the body can turn into NAD+, a chemical involved in energy use. This trial tested swallowed NMN. Its results encourage a specific question about physical function. The much larger claim about living longer remains unproved, and a 2025 review of NAD+ precursor trials found limited human efficacy and sparse evidence about individual tissues.
A well-controlled repeat of the walking result would delight me. Extra distance seems a more useful ambition than an unspecified younger body.
Peptides at home
The appeal of “peptides at home” is easy to understand. An injury interrupts ordinary movement; a skin concern turns up in the mirror; low desire can become a source of distress. Those are recognisable problems. The four substances here have been studied for very different parts of that life.
“Domestic peptides” and “homeland peptides” are loose descriptions, with no specific molecule or approved use attached. Even the umbrella word peptide stretches: NAD+ is a coenzyme, a helper used by working proteins, while BPC-157, PT-141 and GHK are chains of amino acids. A familiar-sounding category tells very little about a particular preparation.
Home Peptides concerns the life people hope to improve. The pages offer research explanation, without home treatment instructions. Medical approval, the way a substance reaches the body and the product actually tested all remain specific to that substance.
Four everyday aims
For movement, BPC-157’s animal repair findings are intriguing, while human injury trials remain scarce. For energy, the NAD+ precursor trials have repeatedly changed blood chemistry and sometimes physical measures. Bremelanotide’s large trials asked women about desire and the distress caused by its loss. GHK-Cu’s small topical studies pursued visible skin changes.
A menu of interchangeable benefits feels wrong to me here. A comfortable joint, a longer walk and renewed desire require different answers. The comparison puts those aims alongside the results. For a closer look, there are pages on BPC-157 and injuries, NAD+ and physical function, PT-141 and desire and GHK-Cu preparations.